HeyJaredVandana Singh
- Indexed articles, last 90 days
- 11
- Latest publication
- Sep 22, 2026
- Outlet visibility, for Aol
- Top 5K sites
- Earliest in this view
- Aug 27, 2026
Latest articles
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug - AOL (opens the original)
Read excerpt
Compass Therapeutics, Inc.(NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care Compass said the FDA recommended the company run a trial demonstrating a survival benefit before submitting a B
Xenon Stock Reaction Is Overblown: Analyst - AOL (opens the original)
Read excerpt
Xenon Pharmaceuticals Inc.(NASDAQ:XENE)submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures. Simultaneously, the neuroscience-focused biopharmaceutical company announced a voluntary pause on new patient enrollment in its ongoing depression clinical studies following reports of neuropsychiatric adverse events. The regulatory filing relies on clinical data from the Phase 2b X-TOLE and the Phase 3 X-TOLE2 studies.
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails - AOL (opens the original)
Read excerpt
Contineum Therapeutics, Inc.(NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & Johnson(NYSE:JNJ) under a global license and developm
Why Is BioNTech Stock Gaining Monday? - AOL (opens the original)
Read excerpt
On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lung cancer (NSCLC). It focuses on patients
Why Is AstraZeneca Stock Trading Higher Today? - AOL (opens the original)
Read excerpt
AstraZeneca Plc(NYSE:AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in lung cancer treatments alongside mixed findings in advanced breast cancer research. Eight-year follow-up data released on Monday from the ADAURA Phase 3 trial revealed that adjuvant Tagrisso lowered the risk of death by 47% in the primary population and 48% in the overall early-stage EGFR-mutated non-small cell lung cancer group following complete t
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5K sites
For Aol, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.